Therapeutic outcomes with surgical and medical management for primary aldosteronism: protocol for a systematic review and meta-analysis

• Published in: BMJ open Vol. 13; no. 7; p. e072585
• Main Authors: Rocca, Aldo, Gkaniatsa, Eleftheria, Brunese, Maria Chiara, Hessman, Eva, Muth, Andreas, Nwaru, Bright I, Ragnarsson, Oskar, Bobbio, Emanuele, Esposito, Daniela
• Format: Journal Article
• Language: English
• Published: England British Medical Journal Publishing Group 30.07.2023; BMJ Publishing Group LTD; BMJ Publishing Group
• Series: Protocol
• Subjects: Adrenal disorders; Antihypertensives; Blood pressure; Citation management software; Diabetes and Endocrinology; drug therapy; Endocrine disorders; Endocrine tumours; Endocrinology and Diabetes; Endokrinologi och diabetes; Ethnicity; General endocrinology; Heart attacks; Heart failure; Humans; Hyperaldosteronism; Hyperaldosteronism - drug therapy; Hyperaldosteronism - surgery; Hypertension; Medical treatment; Meta-analysis; Meta-Analysis as Topic; Mortality; Neuroendocrine tumors; Observational studies; Potassium; Quality of Life; Research Design; Review Literature as Topic; Stroke; Surgery; Systematic review; Systematic Reviews as Topic; Treatment Outcome; Hypertension; Adrenal disorders; Endocrine tumours; General endocrinology
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2023-072585

IntroductionTreatment strategies for primary aldosteronism (PA) include unilateral adrenalectomy and medical treatment with mineralocorticoid receptor (MR) antagonists. Whether these two different treatment strategies are comparable in mitigating the detrimental effect of PA on outcomes is still debated.ObjectivesThe primary aim of this systematic review is to identify, appraise and synthesise existing literature comparing clinical outcomes after treatment in patients with PA.Methods and analysisA systematic and comprehensive search will be performed using PubMed, Web of Science and EMBASE, for studies published until December 2022. Observational and interventional studies will be eligible for inclusion. The quality of observational studies will be assessed using the Newcastle–Ottawa Scale, while interventional studies will be assessed using the Cochrane Effective Practice Organization of Care tool. The collected evidence will be narratively synthesised. We will perform meta-analysis to pool estimates from studies considered to be homogeneous. Reporting of the systematic review and meta-analysis will be in accordance with the Meta-analysis of Observational Studies in Epidemiology Preferred Reporting Items for Systematic reviews and Meta-Analysis guidelines.Ethics and disseminationAs this study is based solely on the published literature, no ethics approval is required. This review will aim to provide some estimates on outcomes, including survival, rates of clinical and biochemical control, cardiovascular and cerebrovascular events, as well as data on quality of life and renal function, in patients with PA treated surgically or with MR antagonists. The study findings will be presented at scientific meetings and will be published in an international peer-reviewed scientific journal.PROSPERO registration numberCRD42022362506.